Organon & Co.

AI Score

XX

Unlock

14.52
-0.04 (-0.27%)
At close: Mar 28, 2025, 3:59 PM
14.47
-0.31%
After-hours: Mar 28, 2025, 06:31 PM EDT

Company Description

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally.

Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.

The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio.

It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis.

In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss.

The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions.

Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Organon & Co.
Organon & Co. logo
Country United States
IPO Date May 14, 2021
Industry Drug Manufacturers - General
Sector Healthcare
Employees 10,000
CEO Kevin Ali

Contact Details

Address:
30 Hudson Street
Jersey City, New Jersey
United States
Website https://www.organon.com

Stock Details

Ticker Symbol OGN
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001821825
CUSIP Number 68622V106
ISIN Number US68622V1061
Employer ID 46-4838035
SIC Code 2834

Key Executives

Name Position
Kevin Ali Chief Executive Officer & Director
Matthew M. Walsh C.F.A. Executive Vice President & Chief Financial Officer
Aaron Falcione Executive Vice President & Chief Human Resources Officer
Daniel Karp Head of Corporate Development
Jennifer Halchak Head of Investor Relations
Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing & Supply
Kirke Weaver Executive Vice President, General Counsel & Corporate Secretary
Rebecca Lowell Edwards Chief Communications Officer
Susan O'Neal Chief Ethics & Compliance Officer
Vittorio Nisita Executive Vice President & Head of Global Business Services

Latest SEC Filings

Date Type Title
Feb 28, 2025 10-K Annual Report
Feb 24, 2025 4 Filing
Feb 24, 2025 4 Filing
Feb 24, 2025 4 Filing
Feb 24, 2025 4 Filing
Feb 24, 2025 4 Filing
Feb 24, 2025 4 Filing
Feb 13, 2025 8-K Current Report
Jan 21, 2025 8-K Current Report
Dec 23, 2024 8-K Current Report